MedTrace Logo

Cerebrospinal Fluid Kinetics of Urolithin A

NCT07517913 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-29

No results posted yet for this study

Summary

The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).

Conditions

  • Healthy Adult

Interventions

DIETARY_SUPPLEMENT

Mitopure

Mitopure is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health

DIETARY_SUPPLEMENT

Placebo

Placebo supplement

Sponsors & Collaborators

  • Mprex Healthcare Pvt. Ltd.

    collaborator UNKNOWN

  • Amazentis SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-04-01
Completion
2027-06-01

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07517913 on ClinicalTrials.gov